Cancer center trials at st barnabas medical center
Download
1 / 19

Cancer Center Trials at St. Barnabas Medical Center - PowerPoint PPT Presentation


  • 176 Views
  • Updated On :

Cancer Center Trials at St. Barnabas Medical Center. Oncology clinical research at Saint Barnabas Medical Center (SBMC) is supported by a staff of three.

Related searches for Cancer Center Trials at St. Barnabas Medical Center

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Cancer Center Trials at St. Barnabas Medical Center' - marijke


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Slide2 l.jpg

  • Oncology clinical research at Saint Barnabas Medical Center (SBMC) is supported by a staff of three.

  • The clinical research group manages the studies in the Cancer Center (Medical Oncology) and The Department of Radiation Oncology. In all, there are 12 physicians who make up this group of oncologists.


Slide3 l.jpg


Slide4 l.jpg


Slide5 l.jpg

  • SBMC participates in clinical trials sponsored by several National Cancer Institute cooperative groups and pharmaceutical companies.

  • SBMC is considered a member accessible to trials from CALGB, NSABP, and RTOG.

  • Our membership to CTSU allows for participation in a wide range of other NCI cooperative group trials as well.


Slide6 l.jpg


Slide7 l.jpg


Slide8 l.jpg

Review of Cancer Center following sites of disease:

Open Trials


Slide9 l.jpg

Breast Cancer Trials Stage I, II, III following sites of disease:

  • ECOG E5103 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

  • NSABP B-39 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) forWomen with Stage 0, I, or II Breast Cancer

  • IBCSG 24-02 A Phase III Trial Evaluating the Role of Ovarian Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Breast Cancer (SOFT)

  • SWOG S0307 Phase III Trial of Bisphosphonates ( Zoledronic acid Vs. Clodronate Vs. Ibandronate) as Adjuvant Therapy for Primary Breast Cancer.


Slide10 l.jpg

  • NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • NCCTG N063D/ALTTO Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study:  A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

  • CALGB 369901 Observational Cohort Study: chemotherapy decisions and outcomes in women age 65 or older with operable, newly diagnoses breast cancer.

  • WYETH 3144A2-3004 WW A Randomized Double-Blind Placebo Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast  


Slide11 l.jpg

Breast Cancer Trials Metastatic Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • CZOL446E2352 A prospective, randomized, stratified, placebo-controlled, multi-center, 2-arm trial of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer.

  • TOC4129g A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer

  • CALGB 40302 Endocrine Therapy With or Without Inhibition of EGF & HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatanib for Postmenopausal Women with ER &/or PR Positive Advanced Breast Cancer

  • Celsion A Phase I-II Study Evaluating the Maximum Tolerated Dose, Pharmacokinetics, Safety, and Efficacy of Microwave Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients With Breast Cancer Recurrence at the Chest Wall


Slide12 l.jpg

Multiple Myeloma Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • C05009 Randomized Phase III study of 3 Novel treatment regimens in subjects with previously untreated multiple myeloma who are not considered candidates for high dose chemotherapy and autologous stem cell transplantation: Velcade (Bortezomib), Thalomid (Thalidomide), and Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD) vs. Velcade, Melphalan, and Prednisone (VMP) 


Slide13 l.jpg

Gastrointestinal, Metastatic Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • SWOG S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) As Second-Line Therapy For Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, XELOX


Slide14 l.jpg

Gastrointestinal STAGE I, II, III Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • ECOG E5202 A Randomized Phase III Study Comparing 5FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers


Slide15 l.jpg

Genitourinary Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • ECOG E2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma 


Slide16 l.jpg

Brain, Adjuvant Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • RTOG 0825 Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab vs. Conventional Concurrent Chemoradiation and Adjuvant Temozolomide In Patients with Newly Diagnosed Glioblastoma

    Brain, Metastatic

  • RTOG 0614 A Randomized Phase III Double-Blind Placebo Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients receiving Whole Brain Radiotherapy 


Slide17 l.jpg

Gynecological Cancers, Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast CancerOvarian

  • AVF4095g A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovary, Primary Peritoneal or Fallopian Tube Carcinoma  


Upcoming trial l.jpg
Upcoming trial Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • Collaboration with Genomic Health for participation in a Registry Study for Oncotype DX in Breast Cancer in the Neo-adjuvant and Adjuvant setting


Slide19 l.jpg
For more information on any of our studies contact: Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast CancerElyce Hirtler, Research Manager [email protected]


ad